ArticleVaccine: X2022

Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study.

Xavier Sáez-Llorens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.